22 vials of compounded tirzepatide recalled in the US over lack of sterility assurance
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one vial of NAD+ injection because their sterility cannot be assured.
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one vial of NAD+ injection because their sterility cannot be assured.
On 20 October 2026 the FDA approved GSK's Hibsago (bepirovirsen) injection for chronic hepatitis B.
In October 2026 the EMA's human medicines committee recommended making Nyxoid (naloxone) available without a prescription.
On 16 October 2026 the EMA's human medicines committee recommended authorising Foundayo (orforglipron) in the EU.
On 15 October 2026 the EMA's human medicines committee adopted a positive opinion extending the indication of AstraZeneca's H5N1 pandemic vaccine.
The UK medicines regulator and West Midlands Police seized more than 12,000 fake weight-loss pens in a raid on 14 October 2026.
On 9 October 2026 the FDA approved Hovilpri (pritelivir) tablets for herpes simplex lesions in immunocompromised adults.
Nothing more to show